Rapid detection of glycopeptide-resistant enterococci: impact on decision-making and costs. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Antimicrobial Resistance and Infection Control Year : 2013

Rapid detection of glycopeptide-resistant enterococci: impact on decision-making and costs.


BACKGROUND: According to French national recommendations, the detection of a patient colonized with glycopeptide-resistant enterococci (GRE) leads to interruption of new admissions and transfer of contact patients (CPs) to another unit or healthcare facility, with weekly screening of CPs. FINDINGS: We evaluated the medical and economic impact of a pragmatic adaptation of national guidelines associated with a real-time PCR (RTP) (Cepheid XpertTM vanA/vanB) as part of the strategy for controlling GRE spread in two medical wards. Screening was previously performed using chromogenic selective medium (CSM). Turn around time (TAT), costs of tests and cost of missed patient days were prospectively collected. In February 2012, the identification of GRE in one patient in the diabetology ward led to the screening of 31 CPs using CSM; one secondary case was identified in a CP already transferred to the Nephrology ward. Awaiting the results of SCM (median TAT, 70.5 h), 41 potential patient days were missed, due to interruption of admissions. The overall cost (screening tests + missing patient.days) was estimated at 14, 302.20 [euro sign]. The secondary case led to screening of 22 CPs in the Nephrology ward using RTP. Because of a short median TAT of 4.6 h, we did not interrupt admissions and patients' transfers. Among 22 CPs, 19 (86%) were negative for vanA, 2 were positive for vanB and 3 had invalid results needing CSM. The overall cost of the strategy was estimated at 870.40 [euro sign] (cost of screening tests only), without missing patient days. CONCLUSION: The rapid PCR test for vanA-positive GRE detection both allowed rapid decision about the best infection control strategy and prevented loss of income due to discontinuation of patient transfers and admissions.
Fichier principal
Vignette du fichier
2047-2994-2-30.pdf (139.19 Ko) Télécharger le fichier
2047-2994-2-30.xml (39.05 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other

Dates and versions

inserm-00903906 , version 1 (13-11-2013)



Gabriel Birgand, Raymond Ruimy, Michael Schwarzinger, Isabelle Lolom, Gisèle Bendjelloul, et al.. Rapid detection of glycopeptide-resistant enterococci: impact on decision-making and costs.. Antimicrobial Resistance and Infection Control, 2013, 2 (1), pp.30. ⟨10.1186/2047-2994-2-30⟩. ⟨inserm-00903906⟩
250 View
242 Download



Gmail Facebook X LinkedIn More